Why Did CEL-SCI Soar 66.7%? Saudi Partnership, Stock Split

On July 11, 2025, CEL-SCI's stock surged by 66.7% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

CEL-SCI Corporation has announced a strategic partnership with a leading Saudi Arabian pharmaceutical company. This collaboration aims to advance the use of Multikine in the treatment of head and neck cancer, a move that could significantly impact the company's market position and future growth prospects.

In addition to this partnership, CEL-SCI has also performed a 1 for 30 reverse stock split. This action reduces the number of outstanding shares, which can lead to an increase in the stock price per share, potentially making the stock more attractive to certain investors.

These developments highlight CEL-SCI's commitment to innovation and expansion in the biotechnology sector, particularly in the field of cancer treatment. The company's focus on boosting the immune system of cancer patients before surgery aligns with its mission to provide effective and groundbreaking therapies.